Cytokeratin 10 (CK10) expression in cancer: A tissue microarray study on 11,021 tumors
Standard
Cytokeratin 10 (CK10) expression in cancer: A tissue microarray study on 11,021 tumors. / Uhlig, Ria; Abboud, Moussa; Gorbokon, Natalia; Lennartz, Maximilian; Dwertmann Rico, Sebastian; Kind, Simon; Reiswich, Viktor; Viehweger, Florian; Kluth, Martina; Hube-Magg, Claudia; Bernreuther, Christian; Büscheck, Franziska; Clauditz, Till S; Fraune, Christoph; Hinsch, Andrea; Jacobsen, Frank; Krech, Till; Lebok, Patrick; Steurer, Stefan; Burandt, Eike; Minner, Sarah; Marx, Andreas; Simon, Ronald; Sauter, Guido; Menz, Anne.
In: ANN DIAGN PATHOL, Vol. 60, 152029, 10.2022.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cytokeratin 10 (CK10) expression in cancer: A tissue microarray study on 11,021 tumors
AU - Uhlig, Ria
AU - Abboud, Moussa
AU - Gorbokon, Natalia
AU - Lennartz, Maximilian
AU - Dwertmann Rico, Sebastian
AU - Kind, Simon
AU - Reiswich, Viktor
AU - Viehweger, Florian
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Bernreuther, Christian
AU - Büscheck, Franziska
AU - Clauditz, Till S
AU - Fraune, Christoph
AU - Hinsch, Andrea
AU - Jacobsen, Frank
AU - Krech, Till
AU - Lebok, Patrick
AU - Steurer, Stefan
AU - Burandt, Eike
AU - Minner, Sarah
AU - Marx, Andreas
AU - Simon, Ronald
AU - Sauter, Guido
AU - Menz, Anne
N1 - Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2022/10
Y1 - 2022/10
N2 - Cytokeratin 10 (CK10) is a type I acidic low molecular weight cytokeratin which is mainly expressed in keratinizing squamous epithelium of the skin. Variable levels of CK10 protein have been described in squamous carcinomas of different sites and in some other epithelial neoplasms. To comprehensively determine the prevalence of CK10 expression in normal and neoplastic tissues, a tissue microarray containing 11,021 samples from 131 different tumor types and subtypes was analyzed by immunohistochemistry. CK10 immunostaining was detectable in 41 (31.3 %) of 131 tumor categories, including 18 (13.7 %) tumor types with at least one strongly positive case. The highest rate of positive staining was found in squamous cell carcinomas from various sites of origin (positive in 18.6 %-66.1 %) and in Warthin tumors of salivary glands (47.8 %), followed by various tumor entities known to potentially exhibit areas with squamous cell differentiation such as teratomas (33.3 %), basal cell carcinomas of the skin (14.3 %), adenosquamous carcinomas of the cervix (11.1 %), and several categories of urothelial neoplasms (3.1 %-16.8 %). In a combined analysis of 956 squamous cell carcinomas from 11 different sites of origin, reduced CK10 staining was linked to high grade (p < 0.0001) and advanced stage (p = 0.0015) but unrelated to HPV infection. However, CK10 staining was not statistically related to grade (p = 0.1509) and recurrence-free (p = 0.5247) or overall survival (p = 0.5082) in 176 cervical squamous cell carcinomas. In the urinary bladder, CK10 staining occurred more commonly in muscle-invasive (17.7 %) than in non-invasive urothelial carcinomas (4.0 %-6.0 %; p < 0.0001). In summary, our data corroborate a role of CK10 as a suitable marker for mature, keratinizing squamous cell differentiation in epithelial tissues. CK10 immunohistochemistry may thus be instrumental for a more objective evaluation of the clinical significance of focal squamous differentiation in cancer.
AB - Cytokeratin 10 (CK10) is a type I acidic low molecular weight cytokeratin which is mainly expressed in keratinizing squamous epithelium of the skin. Variable levels of CK10 protein have been described in squamous carcinomas of different sites and in some other epithelial neoplasms. To comprehensively determine the prevalence of CK10 expression in normal and neoplastic tissues, a tissue microarray containing 11,021 samples from 131 different tumor types and subtypes was analyzed by immunohistochemistry. CK10 immunostaining was detectable in 41 (31.3 %) of 131 tumor categories, including 18 (13.7 %) tumor types with at least one strongly positive case. The highest rate of positive staining was found in squamous cell carcinomas from various sites of origin (positive in 18.6 %-66.1 %) and in Warthin tumors of salivary glands (47.8 %), followed by various tumor entities known to potentially exhibit areas with squamous cell differentiation such as teratomas (33.3 %), basal cell carcinomas of the skin (14.3 %), adenosquamous carcinomas of the cervix (11.1 %), and several categories of urothelial neoplasms (3.1 %-16.8 %). In a combined analysis of 956 squamous cell carcinomas from 11 different sites of origin, reduced CK10 staining was linked to high grade (p < 0.0001) and advanced stage (p = 0.0015) but unrelated to HPV infection. However, CK10 staining was not statistically related to grade (p = 0.1509) and recurrence-free (p = 0.5247) or overall survival (p = 0.5082) in 176 cervical squamous cell carcinomas. In the urinary bladder, CK10 staining occurred more commonly in muscle-invasive (17.7 %) than in non-invasive urothelial carcinomas (4.0 %-6.0 %; p < 0.0001). In summary, our data corroborate a role of CK10 as a suitable marker for mature, keratinizing squamous cell differentiation in epithelial tissues. CK10 immunohistochemistry may thus be instrumental for a more objective evaluation of the clinical significance of focal squamous differentiation in cancer.
KW - Biomarkers, Tumor/analysis
KW - Carcinoma, Adenosquamous
KW - Carcinoma, Squamous Cell/diagnosis
KW - Female
KW - Humans
KW - Immunohistochemistry
KW - Keratins/analysis
KW - Urothelium
U2 - 10.1016/j.anndiagpath.2022.152029
DO - 10.1016/j.anndiagpath.2022.152029
M3 - SCORING: Journal article
C2 - 36029589
VL - 60
JO - ANN DIAGN PATHOL
JF - ANN DIAGN PATHOL
SN - 1092-9134
M1 - 152029
ER -
